Nu Skin Enterprises Inc. (Provo, Utah) has signed an agreement to acquire NOX Technologies Inc. (Malvern, Pa.), a biotechnology and bio-diagnostic company, for $12.5 million. The agreement includes previously licensed technology already used in connection with Nu Skin's anti-aging research efforts. Established in 2003, NOX Technologies focuses on the identification, characterization and detection of cell surface proteins related to aging. The company has identified agents that interact with age-related ECTO-NOX proteins (arNOX). Its discovery of specific inhibitors of arNOX that potentially ameliorate skin damage and the signs of aging led to Nu Skin's development of certain skin care products. “The acquisition of NOX Technologies demonstrates our ongoing commitment to scientific innovation and provides us with additional tools to target the sources of aging,” said Chief Scientific Officer Joe Chang.
Disclaimer: NCN does not warrant the accuracy, reliability, or timeliness of any NCN news item. Before relying on any NCN News item the information should be independently verified.
For more finance and investment information, visit Nutrition Capital Network news